• The global Prescription Digital Therapeutic Market was valued at US$ 105.3 million in 2023 and is predicted to reach US$ 1.6 billion by 2030, exhibiting a Compound Annual Growth Rate (CAGR) of 45.0% during the forecast period (2023-2030).
Report Studies
• Prescription Digital Therapeutics (PDTs) are software-based medical treatments that are prescribed by healthcare providers to treat specific medical conditions. These treatments are designed to deliver evidence-based therapeutic interventions through devices such as smartphones, tablets, or computers. PDTs undergo rigorous clinical trials and regulatory approval, similar to traditional pharmaceutical drugs, to ensure their safety and effectiveness.
• They are used to treat a variety of conditions, including mental health disorders, substance use disorders, diabetes management, and chronic diseases. PDTs can provide real-time monitoring, personalized feedback, and support, often in conjunction with traditional therapies or medications.
• The global key manufacturers of Prescription Digital Therapeutic include Better Therapeutics, BigHealth, Biofourmis, Click Therapeutics, Happify, Limbix Health, Medtronic, NuvoAir AB and Omada Health, etc. in 2023, the global top five players have a share approximately % in terms of revenue.
Email: help@24marketreports.com Call: +1(646)-781-7170 (Int'l)
